SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
SAN DIEGO, Sept. 06, 2017 -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Tuesday, September 12, at 10:50 a.m. ET at the Rodman & Renshaw 19th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 10-12, 2017, at Lotte New York Palace Hotel in New York City. A webcast of the company’s presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.
Contact: Andrew Hopkins (858) 646-1127 Website: www.vical.com
